Clinical Trial

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2024-02-16; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2024-09-25
Trial Details
NCT Number NCT06274047
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Janssen Scientific Affairs, LLC
Conditions Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Enrollment 120 participants
Start Date 2024-09-10
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22